Drug data last refreshed 21h ago · AI intelligence enriched 5d ago
Cetirizine HCl is a second-generation H1-receptor antagonist indicated for allergic rhinitis and urticaria. Administered orally as a capsule, it crosses the blood-brain barrier minimally, reducing sedation compared to first-generation antihistamines. The drug works by selectively blocking histamine H1 receptors, thereby reducing allergic symptoms.
As LOE approaches, commercial teams face significant generic erosion; expect smaller dedicated teams and shift toward cost-management and brand-line extension strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis
Food Study of Cetirizine HCl Tablets 10 mg and Zyrtec® 10 mg
Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg
Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)
Worked on CETIRIZINE HYDROCHLORIDE ALLERGY at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
This product offers limited career growth given its LOE-approaching status and zero linked job openings. Working on cetirizine involves managing decline, optimizing generics transition, and protecting market share against commoditization. Career value lies in gaining experience in lifecycle management and mature product strategy rather than innovation or growth.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo